Pharsight

Drugs with SPC(s)

1. Amzeeq patents expiration

Can you believe AMZEEQ received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10265404 JOURNEY Compositions, gels and foams with rheology modulators and uses thereof
Oct, 2030

(6 years from now)

US10517882 JOURNEY Method for healing of an infected acne lesion without scarring
Oct, 2030

(6 years from now)

US10086080 JOURNEY Topical tetracycline compositions
Oct, 2030

(6 years from now)

US10137200 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Oct, 2030

(6 years from now)

US8992896 JOURNEY Topical tetracycline compositions
Oct, 2030

(6 years from now)

US8945516 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Oct, 2030

(6 years from now)

US10213512 JOURNEY Topical tetracycline compositions
Oct, 2030

(6 years from now)

US9675700 JOURNEY Topical tetracycline compositions
Oct, 2030

(6 years from now)

US10821187 JOURNEY Compositions, gels and foams with rheology modulators and uses thereof
Oct, 2030

(6 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 October, 2019

Treatment: Treatment of non-nodular acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of AMZEEQ before it's drug patent expiration?
More Information on Dosage

AMZEEQ family patents

Family Patents

2. Auvelity patents expiration

AUVELITY's oppositions filed in EPO
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020389 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11197839 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11517543 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10799497 AXSOME Combination of dextromethorphan and bupropion for treating depression
Nov, 2034

(10 years from now)

US9408815 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10512643 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9205083 AXSOME Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Nov, 2034

(10 years from now)

US9168234 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10064857 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9238032 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(10 years from now)

US11207281 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10772850 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9867819 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11096937 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10966941 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10945973 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9314462 AXSOME Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9700553 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11478468 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10058518 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11298351 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11524007 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11291665 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11524008 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10874664 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11253492 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10463634 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11129826 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10874663 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10806710 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11058648 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11291638 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11285146 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11426401 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10894047 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10898453 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11364233 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10874665 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10548857 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11311534 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11234946 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11344544 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11185515 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10881657 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11382874 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10864209 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9278095 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9968568 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US10251879 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11229640 AXSOME Combination of dextromethorphan and bupropion for treating depression
Nov, 2034

(10 years from now)

US11517542 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11273134 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10092561 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(10 years from now)

US11357744 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11433067 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9457025 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(10 years from now)

US10092560 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9763932 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11123343 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9486450 AXSOME Hydroxybupropion and related compounds as modulators of drug plasma levels
Nov, 2034

(10 years from now)

US10105327 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9861595 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US10596167 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(10 years from now)

US9198905 AXSOME Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9375429 AXSOME Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Nov, 2034

(10 years from now)

US11141388 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10786469 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11253491 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10966974 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11497721 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11213521 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11090300 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11147808 AXSOME Method of decreasing the fluctuation index of dextromethorphan
Nov, 2034

(10 years from now)

US11426370 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10894046 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9707191 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9370513 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11273133 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11419867 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10080727 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11510918 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11191739 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10105361 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US10933034 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10881624 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9700528 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11298352 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10786496 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11285118 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11141416 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10780066 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US10925842 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

US10966942 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

US10940124 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

US10780064 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 18, 2025

Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient

Market Authorisation Date: 18 August, 2022

Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of AUVELITY before it's drug patent expiration?
More Information on Dosage

AUVELITY family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Caplyta patents expiration

Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10464938 INTRA-CELLULAR Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof
Mar, 2028

(3 years from now)

US10117867 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(4 years from now)

US9616061 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(4 years from now)

US8598119 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 20, 2024
New Indication(I-882) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 21 December, 2023

Market Authorisation Date: 22 April, 2022

Treatment: Treatment of bipolar depression; Treatment of schizophrenia

Dosage: CAPSULE;ORAL

More Information on Dosage

CAPLYTA family patents

Family Patents

4. Copiktra patents expiration

Can you believe COPIKTRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8193182 SECURA Substituted isoquinolin-1(2H)-ones, and methods of use thereof
Feb, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216982 SECURA Certain chemical entities, compositions and methods
Jan, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-208) Sep 24, 2025
Orphan Drug Exclusivity(ODE-209) Sep 24, 2025
New Chemical Entity Exclusivity(NCE) Sep 24, 2023

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: 24 September, 2022

Market Authorisation Date: 24 September, 2018

Treatment: For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE;ORAL

More Information on Dosage

COPIKTRA family patents

Family Patents

5. Drospirenone patents expiration

DROSPIRENONE's oppositions filed in EPO
Can you believe DROSPIRENONE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10179140 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US10849857 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US11291633 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11413249 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US10603281 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US11123299 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11291632 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US9603860 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US11439598 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11504334 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 29, 2025

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 29 June, 2022

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage

DROSPIRENONE family patents

Family Patents

6. Duzallo patents expiration

Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8283369 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Nov, 2028

(4 years from now)

US10183012 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Nov, 2028

(4 years from now)

US8546437 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Apr, 2029

(4 years from now)

US8084483 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Aug, 2029

(5 years from now)

US8357713 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Dec, 2029

(5 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET;ORAL

More Information on Dosage

DUZALLO family patents

Family Patents

7. Ezallor Sprinkle patents expiration

Can you believe EZALLOR SPRINKLE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10413543 SUN PHARM Stable multiparticulate pharmaceutical composition of rosuvastatin
Feb, 2036

(11 years from now)

Drugs and Companies using ROSUVASTATIN CALCIUM ingredient

Market Authorisation Date: 18 December, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

EZALLOR SPRINKLE family patents

Family Patents

8. Fleqsuvy patents expiration

Can you believe FLEQSUVY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446246 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(13 years from now)

US11324696 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(13 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 04 February, 2022

Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis

Dosage: SUSPENSION;ORAL

How can I launch a generic of FLEQSUVY before it's drug patent expiration?
More Information on Dosage

FLEQSUVY family patents

Family Patents

9. Galafold patents expiration

Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10406143 AMICUS THERAP US Methods for treatment of fabry disease
May, 2027

(2 years from now)

US10383864 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(2 years from now)

US9987263 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(2 years from now)

US9480682 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(2 years from now)

US11241422 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(2 years from now)

US9000011 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-205) Aug 10, 2025
New Chemical Entity Exclusivity(NCE) Aug 10, 2023

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage

GALAFOLD family patents

Family Patents

10. Givlaari patents expiration

GIVLAARI IPR and PTAB Proceedings
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9708610 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(5 months ago)

US9150605 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Aug, 2025

(1 year, 2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2024
Orphan Drug Exclusivity(ODE-273) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 21 November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GIVLAARI family patents

Family Patents

11. Gocovri patents expiration

GOCOVRI's oppositions filed in EPO
Can you believe GOCOVRI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9867791 ADAMAS OPERATIONS Method of administering amantadine prior to a sleep period
Dec, 2030

(6 years from now)

US9867792 ADAMAS OPERATIONS Method of administering amantadine prior to a sleep period
Dec, 2030

(6 years from now)

US11197835 ADAMAS OPERATIONS Method of administering amantadine prior to a sleep period
Dec, 2030

(6 years from now)

US8741343 ADAMAS OPERATIONS Method of administering amantadine prior to a sleep period
Dec, 2030

(6 years from now)

US9867793 ADAMAS OPERATIONS Method of administering amantadine prior to a sleep period
Dec, 2030

(6 years from now)

US9877933 ADAMAS OPERATIONS Method of administering amantadine prior to a sleep period
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-153) Aug 24, 2024
Orphan Drug Exclusivity(ODE) Aug 24, 2024
New Indication(I-769) Aug 24, 2020
New Product(NP) Aug 24, 2020

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 August, 2017

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and increasing on time with...

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of GOCOVRI before it's drug patent expiration?
More Information on Dosage

GOCOVRI family patents

Family Patents

12. Kloxxado patents expiration

Can you believe KLOXXADO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722510 HIKMA Liquid naloxone spray
Aug, 2034

(10 years from now)

US11135155 HIKMA Liquid naloxone spray
Aug, 2034

(10 years from now)

US10973814 HIKMA Liquid naloxone spray
Aug, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 29, 2024

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 April, 2021

Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients

Dosage: SPRAY;NASAL

How can I launch a generic of KLOXXADO before it's drug patent expiration?
More Information on Dosage

KLOXXADO family patents

Family Patents

13. Leqvio patents expiration

LEQVIO's oppositions filed in EPO
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8232383 NOVARTIS RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
Feb, 2023

(1 year, 3 months ago)

US11078485 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(7 months ago)

US9708610 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(5 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10266825 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(7 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: 22 December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (hefh), by inhibiting expression of the pcsk9 gen...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

LEQVIO family patents

Family Patents

14. Linzess patents expiration

LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7704947 ABBVIE Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(4 months ago)

US7745409 ABBVIE Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(4 months ago)

US8080526 ABBVIE Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(4 months ago)

US7371727 ABBVIE Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(4 months ago)

US7304036 ABBVIE Methods and compositions for the treatment of gastrointestinal disorders
Aug, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110553 ABBVIE Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(4 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-921) Jun 12, 2026
New Strength(NS) Jan 25, 2020
New Chemical Entity Exclusivity(NCE) Aug 30, 2017

Drugs and Companies using LINACLOTIDE ingredient

NCE-1 date: 30 August, 2016

Market Authorisation Date: 25 January, 2017

Treatment: Method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.

Dosage: CAPSULE;ORAL

How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage

LINZESS family patents

Family Patents

15. Livmarli patents expiration

Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11229647 MIRUM Methods for treating cholestasis
Feb, 2040

(15 years from now)

US11497745 MIRUM Methods for treating cholestasis
Feb, 2040

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 29, 2026
Orphan Drug Exclusivity(ODE-429) Mar 13, 2030
New Indication(I-938) Mar 13, 2027
Orphan Drug Exclusivity(ODE-379) Sep 29, 2028
New Patient Population(NPP) Mar 13, 2026
Orphan Drug Exclusivity(ODE-471) Mar 13, 2031

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: 29 September, 2025

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)

Dosage: SOLUTION;ORAL

More Information on Dosage

LIVMARLI family patents

Family Patents

16. Lorbrena patents expiration

Can you believe LORBRENA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8680111 PFIZER Macrocyclic derivatives for the treatment of diseases
Mar, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-218) Nov 02, 2025
Orphan Drug Exclusivity(ODE-219) Nov 02, 2025
Orphan Drug Exclusivity(ODE-217) Nov 02, 2025
Orphan Drug Exclusivity(ODE-349) Mar 03, 2028
New Indication(I-847) Mar 03, 2024
New Chemical Entity Exclusivity(NCE) Nov 02, 2023

Drugs and Companies using LORLATINIB ingredient

NCE-1 date: 02 November, 2022

Market Authorisation Date: 02 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

LORBRENA family patents

Family Patents

17. Mekinist patents expiration

Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7378423 NOVARTIS Pyrimidine compound and medical use thereof
May, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(11 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030
New Product(NP) Mar 16, 2026

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Market Authorisation Date: 16 March, 2023

Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic thera...

Dosage: SOLUTION;ORAL

More Information on Dosage

MEKINIST family patents

Family Patents

18. Nuzyra patents expiration

Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835542 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(13 years from now)

US10383884 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 02, 2023
Generating Antibiotic Incentives Now(GAIN) Oct 02, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: 03 October, 2027

Market Authorisation Date: 02 October, 2018

Treatment: Treatment of community acquired bacterial pneumonia

Dosage: TABLET;ORAL; POWDER;INTRAVENOUS

More Information on Dosage

NUZYRA family patents

Family Patents

19. Onpattro patents expiration

ONPATTRO's oppositions filed in EPO
ONPATTRO IPR and PTAB Proceedings
Can you believe ONPATTRO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8334373 ALNYLAM PHARMS INC Nuclease resistant double-stranded ribonucleic acid
May, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8058069 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(4 years from now)

US8492359 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(4 years from now)

US9364435 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(4 years from now)

US11141378 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(4 years from now)

US8822668 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(4 years from now)

US8802644 ALNYLAM PHARMS INC Lipid formulation
Oct, 2030

(6 years from now)

US8158601 ALNYLAM PHARMS INC Lipid formulation
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-197) Aug 10, 2025
New Chemical Entity Exclusivity(NCE) Aug 10, 2023

Drugs and Companies using PATISIRAN SODIUM ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ONPATTRO family patents

Family Patents

20. Orladeyo patents expiration

Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11117867 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-333) Dec 03, 2027
New Chemical Entity Exclusivity(NCE) Dec 03, 2025

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

NCE-1 date: 03 December, 2024

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE;ORAL

More Information on Dosage

ORLADEYO family patents

Family Patents

21. Oxlumo patents expiration

Can you believe OXLUMO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10465195 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

US11060093 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

US10487330 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

US9828606 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435692 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-339) Nov 23, 2027
New Chemical Entity Exclusivity(NCE) Nov 23, 2025
Orphan Drug Exclusivity(ODE-415) Oct 06, 2029
New Indication(I-901) Oct 06, 2025

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: 23 November, 2024

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

OXLUMO family patents

Family Patents

22. Phexxi patents expiration

Can you believe PHEXXI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11337989 EVOFEM INC Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
Mar, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 22, 2023

Drugs and Companies using CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE ingredient

Market Authorisation Date: 22 May, 2020

Treatment: Prevention of pregnancy

Dosage: GEL;VAGINAL

How can I launch a generic of PHEXXI before it's drug patent expiration?
More Information on Dosage

PHEXXI family patents

Family Patents

23. Pylarify patents expiration

PYLARIFY's oppositions filed in EPO
Can you believe PYLARIFY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8487129 PROGENICS PHARMS INC Heterodimers of glutamic acid
Nov, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 26, 2026

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

NCE-1 date: 26 May, 2025

Market Authorisation Date: 26 May, 2021

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PYLARIFY family patents

Family Patents

24. Qinlock patents expiration

Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8188113 DECIPHERA PHARMS Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 15, 2025
Orphan Drug Exclusivity(ODE-298) May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: 15 May, 2024

Market Authorisation Date: 15 May, 2020

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

QINLOCK family patents

Family Patents

25. Recarbrio patents expiration

Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 16, 2024
Generating Antibiotic Incentives Now(GAIN) Jul 16, 2029

Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient

NCE-1 date: 16 July, 2028

Market Authorisation Date: 16 July, 2019

Treatment: Treatment of complicated urinary tract infections, including pyelonephritis (cuti)

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

RECARBRIO family patents

Family Patents

26. Seysara patents expiration

Can you believe SEYSARA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9255068 ALMIRALL Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same
Feb, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 01, 2023

Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient

NCE-1 date: 01 October, 2022

Market Authorisation Date: 01 October, 2018

Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydroch...

Dosage: TABLET;ORAL

More Information on Dosage

SEYSARA family patents

Family Patents

27. Signifor Lar Kit patents expiration

Can you believe SIGNIFOR LAR KIT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7473761 RECORDATI RARE Somatostatin analogues
Dec, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822637 RECORDATI RARE Somatostatin analogues
Aug, 2023

(10 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-268) Jun 29, 2025
New Indication(I-785) Jun 29, 2021
Orphan Drug Exclusivity(ODE) Dec 15, 2021
New Chemical Entity Exclusivity(NCE) Dec 14, 2017
New Product(NP) Dec 15, 2017
Orphan Drug Exclusivity(ODE-81) Dec 15, 2021

Drugs and Companies using PASIREOTIDE PAMOATE ingredient

NCE-1 date: 14 December, 2016

Market Authorisation Date: 29 June, 2018

Treatment: Method of treating acromegaly

Dosage: FOR SUSPENSION;INTRAMUSCULAR

More Information on Dosage

SIGNIFOR LAR KIT family patents

Family Patents

28. Slynd patents expiration

SLYND's oppositions filed in EPO
Can you believe SLYND received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11291633 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US10849857 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US9603860 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US11291632 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11413249 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11504334 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US10603281 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US11439598 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11123299 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US10179140 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 23, 2022

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 23 May, 2019

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET;ORAL

How can I launch a generic of SLYND before it's drug patent expiration?
More Information on Dosage

SLYND family patents

Family Patents

29. Tafinlar patents expiration

Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(11 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030
New Product(NP) Mar 16, 2026
Pediatric Exclusivity(PED) Sep 16, 2026

Drugs and Companies using DABRAFENIB MESYLATE ingredient

Market Authorisation Date: 16 March, 2023

Treatment: Tafinlar is indicated, in combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic thera...

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage

TAFINLAR family patents

Family Patents

30. Tibsovo patents expiration

Can you believe TIBSOVO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10653710 SERVIER Combination therapy for treating malignancies
Oct, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-203) Jul 20, 2025
Orphan Drug Exclusivity(ODE-242) May 02, 2026
New Indication(I-875) Aug 25, 2024
New Indication(I-924) Oct 24, 2026
Orphan Drug Exclusivity(ODE-368) Aug 25, 2028
Orphan Drug Exclusivity(ODE-447) Oct 24, 2030
New Indication(I-893) May 25, 2025
New Chemical Entity Exclusivity(NCE) Jul 20, 2023
New Indication(I-816) May 02, 2022

Drugs and Companies using IVOSIDENIB ingredient

NCE-1 date: 20 July, 2022

Market Authorisation Date: 20 July, 2018

Treatment: A method for treating newly diagnosed aml characterized by the presence of a mutant allele of idh1 selected from r132h, r132c, r132l, r132v, r132s and r132gf by administering ivosidenib and azacitidin...

Dosage: TABLET;ORAL

How can I launch a generic of TIBSOVO before it's drug patent expiration?
More Information on Dosage

TIBSOVO family patents

Family Patents

31. Tigecycline patents expiration

Can you believe TIGECYCLINE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855335 AMNEAL Tigecycline composition for injection
Apr, 2033

(8 years from now)

Drugs and Companies using TIGECYCLINE ingredient

Market Authorisation Date: 02 August, 2018

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

TIGECYCLINE family patents

Family Patents

32. Twyneo patents expiration

Can you believe TWYNEO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10420743 GALDERMA LABS LP Methods and compositions for the treatment of acne
Jul, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jul 26, 2024

Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient

Market Authorisation Date: 26 July, 2021

Treatment: Topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage

TWYNEO family patents

Family Patents

33. Verkazia patents expiration

Can you believe VERKAZIA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7973081 HARROW EYE Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(1 year, 7 months from now)

US9956289 HARROW EYE Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(1 year, 7 months from now)

US9220694 HARROW EYE Emulsion compositions containing cetalkonium chloride
Jan, 2026

(1 year, 7 months from now)

US8524779 HARROW EYE Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(1 year, 7 months from now)

US9132071 HARROW EYE Compositions containing quaternary ammonium compounds
Jun, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-358) Jun 23, 2028
New Product(NP) Jun 23, 2024

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 June, 2021

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage

VERKAZIA family patents

Family Patents

34. Welireg patents expiration

Can you believe WELIREG received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9969689 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(10 years from now)

US9908845 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 13, 2026
New Indication(I-931) Dec 14, 2026
Orphan Drug Exclusivity(ODE-364) Aug 13, 2028

Drugs and Companies using BELZUTIFAN ingredient

NCE-1 date: 13 August, 2025

Market Authorisation Date: 13 August, 2021

Treatment: Treatment of adult patients with advanced renal cell carcinoma following a programmed death receptor-1 or programmed death-ligand inhibitor and a vascular endothelial growth factor tyrosine kinase inh...

Dosage: TABLET;ORAL

More Information on Dosage

WELIREG family patents

Family Patents

35. Xyosted (autoinjector) patents expiration

Can you believe XYOSTED (AUTOINJECTOR) received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160751 ANTARES PHARMA INC Hematocrit modulation through needle assisted jet injection of testosterone
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 28, 2021

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

XYOSTED (AUTOINJECTOR) family patents

Family Patents

36. Zeposia patents expiration

ZEPOSIA's oppositions filed in EPO
Can you believe ZEPOSIA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239846 BRISTOL Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 25, 2025
New Indication(I-860) May 27, 2024

Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient

NCE-1 date: 25 March, 2024

Market Authorisation Date: 25 March, 2020

Treatment: Treatment of moderately to severely active ulcerative colitis (uc) in adults

Dosage: CAPSULE;ORAL

More Information on Dosage

ZEPOSIA family patents

Family Patents

37. Zilxi patents expiration

Can you believe ZILXI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945516 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Oct, 2030

(6 years from now)

US9675700 JOURNEY Topical tetracycline compositions
Oct, 2030

(6 years from now)

US10213512 JOURNEY Topical tetracycline compositions
Oct, 2030

(6 years from now)

US10946101 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Oct, 2030

(6 years from now)

US10265404 JOURNEY Compositions, gels and foams with rheology modulators and uses thereof
Oct, 2030

(6 years from now)

US10322186 JOURNEY Topical tetracycline compositions
Oct, 2030

(6 years from now)

US8992896 JOURNEY Topical tetracycline compositions
Oct, 2030

(6 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2020

Treatment: Treatment of inflammatory lesions of rosacea.

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of ZILXI before it's drug patent expiration?
More Information on Dosage

ZILXI family patents

Family Patents

38. Zulresso patents expiration

Can you believe ZULRESSO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10251894 SAGE THERAP Anticonvulsant activity of steroids
Nov, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 17, 2024
New Patient Population(NPP) Jun 16, 2025

Drugs and Companies using BREXANOLONE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: Method of treating postpartum depression

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ZULRESSO family patents

Family Patents